Kaitlyn Kosko

Lung Cancers Today

Patients of Hispanic/Latino ethnicity have a greater prevalence of certain lung cancer driver mutations than Asian and European individuals, according to a recent meta-analysis.A team of researchers, led by Rafael Parra-Medina, MD, PhD, examined how common genes, such as ALK, BRAF, EGFR, HER2, KRAS, MET, NTRK, RET, and ROS1, were in this specific population. They used the EMBASE, LILACS, MEDLINE, and Virtual Health Library databases to identify studies that were included in the analysis.Fifty-five articles met inclusion and exclusion criteria and included Hispanic/Latino patients with lung cancer from the following countries: Argentina, Bolivia, Brazil, Chile, Colombia, Costa Rica, Ecuador, Mexico, Panama, Peru, Puerto Rico, United States, Uruguay, and Venezuela.Half of the patients were men (50.9%), 65.8% had a history of tobacco exposure, and 59.2% had stage IV disease.The researchers discovered that EGFR (22%) and KRAS (14%) were the two most commonly found genes in this population across all the countries. Among the EGFR-positive patients, the most frequent mutations were deletion 19 (10%) and L858R (7%). In patients with KRAS gene mutations, KRASG12C was the most prevalent mutation (7%).The prevalence of the other mutation drivers was as follows: ALK (5%); HER2 (4%); MET (3%); ROS1, BRAF, and RET (2%); and NTRK (1%).Because of these differences, the researchers recommended testing Latin American patients with next-generation sequencing (NGS) at different stages and enrolling them in clinical trials to get a clear understanding of the prevalence of actionable driver mutations.

Cecilia Brown

Beamion LUNG-1: Zongertinib Shows ‘Significant’ Activity in Patients With NSCLC Harboring HER2 Mutations

Conference Coverage

Zoldonrasib Shows ‘Encouraging’ Activity in Patients With NSCLC Harboring KRAS G12D Mutation

KRAS+ NSCLC

HARMONi-6 Meets Primary End Point of Progression-Free Survival in Squamous NSCLC

Immunotherapy in NSCLC

Stephen V. Liu, MD

MARIPOSA, LAURA, and SAVANNAH: Dr. Liu Weighs In on New Data in EGFR-Positive NSCLC

EGFR+ NSCLC

Lung Cancers Today Editors

Loïc Le Marchand, MD, PhD, MPH, to Receive AACR-American Cancer Society Award for Research Excellence in Cancer Epidemiology and Prevention

Lung Cancer

Alice T. Shaw, MD, PhD, to Receive AACR-Joseph H. Burchenal Award for Outstanding Achievement in Clinical Cancer Research

ALK+ NSCLC

Latest News

EGFR, KRAS Most Prevalent Mutations in Hispanic, Latino Patients With Lung Cancer

Patients of Hispanic/Latino ethnicity have a greater prevalence of certain lung cancer driver mutations.

EGFR, KRAS Most Prevalent Mutations in Hispanic/Latino Patients With Lung Cancer